Jeff Mann serves as the General Counsel and Head of Business Development for embecta. Jeff brings 22 years of medical device and law firm experience to embecta, including leadership in M&A, securities, corporate governance, intellectual property, commercial transactions, compliance and litigation, and he has deep roots in the medical, pharmaceutical and biotechnology sectors.
Most recently, he served as General Counsel and Corporate Secretary of Cantel Medical Corp., a global medical products company focused on infection prevention products, where he was responsible for the global legal, compliance, and environmental health and safety teams. He also led several business development projects, including the eventual sale of Cantel to Steris plc for $4.6 billion. Simultaneously, he held a year-long assignment as global leader of Cantel’s R&D team, managing a team of 130 associates based in Germany, Italy, the United Kingdom and the U.S.
Prior to Cantel, he spent 14 years with Boston Scientific Corporation in roles of increasing responsibility, including M&A, venture capital investments, SEC and corporate governance patent strategy, litigation, and business unit support for the $3 billion MedSurg group. He also served on the Board of Directors of Preventice Solutions and as Chair of its Compensation Committee.
Jeff holds a Bachelor of Science in Civil and Environmental Engineering from Lafayette College in Easton, PA, and a J.D. from Boston College Law School, magna cum laude.
What is Jeffrey Z. Mann's net worth?
The estimated net worth of Jeffrey Z. Mann is at least $489.14 thousand as of August 10th, 2023. Mr. Mann owns 55,333 shares of Embecta stock worth more than $489,144 as of March 30th. This net worth evaluation does not reflect any other investments that Mr. Mann may own. Learn More about Jeffrey Z. Mann's net worth.
How do I contact Jeffrey Z. Mann?
Has Jeffrey Z. Mann been buying or selling shares of Embecta?
Jeffrey Z. Mann has not been actively trading shares of Embecta during the last quarter. Most recently, on Thursday, August 10th, Jeffrey Z. Mann bought 4,700 shares of Embecta stock. The stock was acquired at an average cost of $21.67 per share, with a total value of $101,849.00. Following the completion of the transaction, the senior vice president now directly owns 55,333 shares of the company's stock, valued at $1,199,066.11. Learn More on Jeffrey Z. Mann's trading history.
Who are Embecta's active insiders?
Are insiders buying or selling shares of Embecta?
During the last year, Embecta insiders bought shares 1 times. They purchased a total of 10,000 shares worth more than $106,000.00. The most recent insider tranaction occured on May, 23rd when Director David F Melcher bought 10,000 shares worth more than $106,000.00. Insiders at Embecta own 1.3% of the company.
Learn More about insider trades at Embecta. Information on this page was last updated on 5/23/2025.
